Client First Investment Management LLC Acquires New Shares in ARK Genomic Revolution ETF $ARKG

Client First Investment Management LLC acquired a new position in ARK Genomic Revolution ETF (BATS:ARKG) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 61,321 shares of the company’s stock, valued at approximately $2,579,000. ARK Genomic Revolution ETF accounts for 1.1% of Client First Investment Management LLC’s portfolio, making the stock its 16th largest holding. Client First Investment Management LLC owned approximately 0.14% of ARK Genomic Revolution ETF at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in ARKG. Ascentis Independent Advisors acquired a new position in shares of ARK Genomic Revolution ETF in the 1st quarter valued at $26,000. PNC Financial Services Group Inc. raised its holdings in ARK Genomic Revolution ETF by 53.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,088 shares of the company’s stock valued at $29,000 after buying an additional 378 shares during the period. Sunbelt Securities Inc. raised its holdings in ARK Genomic Revolution ETF by 734.3% in the 3rd quarter. Sunbelt Securities Inc. now owns 1,118 shares of the company’s stock valued at $31,000 after buying an additional 984 shares during the period. Western Wealth Management LLC acquired a new position in ARK Genomic Revolution ETF in the first quarter valued at about $37,000. Finally, Strategic Wealth Investment Group LLC acquired a new position in ARK Genomic Revolution ETF in the second quarter valued at about $38,000.

ARK Genomic Revolution ETF Stock Up 6.1%

Shares of ARKG stock opened at $43.04 on Friday. The company has a 50-day moving average of $38.55 and a two-hundred day moving average of $32.47. ARK Genomic Revolution ETF has a 1-year low of $23.20 and a 1-year high of $44.47.

ARK Genomic Revolution ETF Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.